Abstract

The colon is largely impacted by the chronic gastrointestinal inflammatory illness known as ulcerative colitis (UC). Patients with UC experience chronic inflammation of the colon's surface mucosa, crypt epithelium, and/or submucosa, which results in bloody diarrhoea, stomach pain, weight loss, and fever. Although UC symptoms are similar in both adults and children, pediatric-onset UC is more usually associated with acute severe exacerbations because it tends to be more severe than in adult patients. This study's primary goal is to evaluate infliximab pharmacokinetics in children with ulcerative colitis (UC).